Clinical Trial Update: Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers [Phase 3]

View source ↗

Summary

A Phase 3 study of Rosiglitazone XR in subjects with mild-to-moderate Alzheimer's disease was terminated, and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Rosiglitazone XR (rosiglitazone extended-release)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2017-11-08